Table 2.
Dosimetric sensitivity of OAR clinical maximum dose, D2cm 3
| Bladder [Gy] | Rectum [Gy] | Sigmoid [Gy] | ||||
|---|---|---|---|---|---|---|
| Param/Plan | VMAT | IMPT | VMAT | IMPT | VMAT | IMPT |
| Standard | 1.77 ± 0.00 | 1.75 ± 0.00 | 1.75 ± 0.00 | 1.75 ± 0.01 | 1.75 ± 0.01 | 1.74 ± 0.00 |
| SIB | 1.92 ± 0.04 | 1.80 ± 0.01 | 1.85 ± 0.02 | 1.82 ± 0.02 | 1.81 ± 0.02 | 1.78 ± 0.01 |
| SIB 3 mm shift | 2.11 ± 0.08 | 2.02 ± 0.06 | 2.04 ± 0.04 | 2.00 ± 0.05 | 1.93 ± 0.05 | 1.88 ± 0.05 |
| SIB 5 mm shift | 2.23 ± 0.10 | 2.20 ± 0.09 | 2.16 ± 0.06 | 2.15 ± 0.06 | 2.02 ± 0.08 | 1.97 ± 0.08 |
Dosimetric sensitivity analysis estimating increase of D2cm 3 to OARs from shifts towards the high dose area potentially caused by tumour shrinkage
Values are EQD2 per fraction (α/β = 3) and in mean ± standard deviation of the mean